ArticleFrontiers in oncology2026
A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04930536 (A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the safety and clinical outcomes of acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or refractory/relapsed mantle cell lymphoma (MCL) in a real-world setting in India. Methods: This Phase IV, open-label, single-arm, multi-center, prospective study included 89 patients with CLL/SLL (treatment naive or one or more prior therapy) and 11 patients with refractory/relapsed MCL who received acalabrutinib capsules 100 mg orally twice daily for six 28-day cycles or until study drug discontinuation. Patients were followed up for 28 days after the drug discontinuation to collect additional safety data. The primary endpoint was the incidence of adverse events (AEs), treatment-emergent AEs (TEAEs), serious adverse events (SAEs), second primary malignancies, and other AEs of clinical interest. Secondary endpoints included objective response rate (ORR) and quality of life. Results: By the end of the follow-up period, 48 (54%) patients in the CLL/SLL cohort and 9 (82%) patients in the MCL cohort reported at least one AE. Of these, 38 (43%) patients in the CLL/SLL cohort and 7 (64%) in the MCL cohort reported TEAEs, with serious TEAEs reported in 9% and 27%, respectively. Three patients in CLL/SLL and two in MCL reported drug-related TEAEs. Drug-related deaths were reported in two MCL patients. Drug discontinuation due to AEs was reported in 3.4% and 18.2% of the CLL/SLL and MCL cohorts, respectively. During the follow-up period, the ORR was 62% in CLL/SLL cohort and 36% in MCL cohort, with quality of life scores maintained throughout. Conclusion: The study demonstrated safety of Acalabrutinib with no new signals and encouraging clinical outcomes in Indian patients with CLL/SLL and MCL, consistent with global clinical trials. ClinicalTrialsgov identifier: NCT04930536.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.